Advances in Multiple Sclerosis and Experimental Demyelinating Diseases

by

Write The First Customer Review

Controversy still exists regarding how early disease-modifying agents (DMA) should be commenced and whether all patients with relapsing-remitting MS should in fact be treated. To answer these questions, it is also important to know the natural history of the disease. MS affects nearly 400,000 people in the United States. With their novel, multifaceted approach to basic science, the authors of this book offer help to clinicians and hope to patients.

Advances in Multiple Sclerosis and Experimental Demyelinating Diseases 2014, Springer, Berlin

ISBN-13: 9783642437830

2008 edition

Trade paperback

Select
Advances in Multiple Sclerosis and Experimental Demyelinating Diseases 2007, Springer, Berlin, Germany

ISBN-13: 9783540736769

2008 edition

Hardcover

Select